Brief: Hansa Biopharma Completes Randomization In Pivotal Phase 3 Us Confides Trial
31/05/2024 13:15
May 31 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA COMPLETES RANDOMIZATION IN PIVOTAL PHASE 3
US
CONFIDES TRIAL
* HANSA BIOPHARMA AB: DATA FROM TRIAL EXPECTED TO SUPPORT
BLA
SUBMISSION UNDER ACCELERATED APPROVAL PATHWAY TO FDA IN SECOND
HALF OF 2025
Source text for Eikon: ID:nPn3gDQp4a
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS